{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:16:40Z","timestamp":1788293800878,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010769","name":"Axencia Galega de Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Spanish Association Against Cancer Scientific Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["INT24\/00023"],"award-info":[{"award-number":["INT24\/00023"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["DTS24\/00083"],"award-info":[{"award-number":["DTS24\/00083"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI22\/00589"],"award-info":[{"award-number":["PI22\/00589"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI25\/00744"],"award-info":[{"award-number":["PI25\/00744"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euros.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:53:27Z","timestamp":1785167607000},"page":"49-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical Impact of Germline Pathogenic Variants in High-risk Prostate Cancer Treated with Radiotherapy"],"prefix":"10.1016","volume":"91","author":[{"given":"Javier","family":"Galego-Carro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Santamari\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blanco-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel E.","family":"Aguado-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Amigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Fuentes-R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Coedo-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Calvo-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Peleteiro-Higuero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Carballo-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Taboada-Valladares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"G\u00f3mez-Caama\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7416-5137","authenticated-orcid":false,"given":"Ana","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.07.002_b0005","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2026.07.002_b0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1200\/JCO.2018.36.6_suppl.130","article-title":"Which patients with localized prostate cancer account for the greatest proportion of prostate cancer deaths?","volume":"36","author":"Nezolosky","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2026.07.002_b0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.eururo.2020.05.009","article-title":"Transcriptomic heterogeneity of Gleason grade group 5 prostate cancer","volume":"78","author":"Kishan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.002_b0020","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/cancers12061550","article-title":"Clinical applications of molecular biomarkers in prostate cancer","volume":"12","author":"Cou\u00f1ago","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.euros.2026.07.002_b0025","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.urolonc.2017.12.022","article-title":"Molecular correlates of intermediate- and high-risk localized prostate cancer","volume":"36","author":"Ye","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2026.07.002_b0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.07.002_b0035","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/s41436-020-0830-5","article-title":"Diagnosing hereditary cancer predisposition in men with prostate cancer","volume":"22","author":"Pritzlaff","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.euros.2026.07.002_b0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2026.07.002_b0045","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.23739","article-title":"Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing","volume":"79","author":"Giri","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2026.07.002_b0050","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14656566.2021.1912015","article-title":"Olaparib and Rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer","volume":"22","author":"Maughan","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.euros.2026.07.002_b0055","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ng.3020","article-title":"A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1","volume":"46","author":"Fachal","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.euros.2026.07.002_b0060","unstructured":"EAU guidelines. Edn. Presented at the EAU Annual Congress Madrid. Spain. ISBN 978-94-92671-29-5; 2025."},{"key":"10.1016\/j.euros.2026.07.002_b0065","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.euros.2026.07.002_b0070","unstructured":"ClinGen. Clinical genome resource SVI General Recommendations for Using ACMG\/AMP Criteria Website. https:\/\/clinicalgenome.org\/working-groups\/sequence-variant-interpretation\/."},{"key":"10.1016\/j.euros.2026.07.002_b0075","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.eururo.2021.09.029","article-title":"Association of inherited mutations in DNA repair genes with localized prostate cancer","volume":"81","author":"Lee","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.002_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/345310","article-title":"Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene","volume":"72","author":"Edwards","year":"2003","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.euros.2026.07.002_b0085","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients","volume":"105","author":"Kote-Jarai","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euros.2026.07.002_b0090","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","article-title":"Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study","volume":"4","author":"Karlsson","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2026.07.002_b0095","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/jamaoncol.2023.3482","article-title":"Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer","volume":"9","author":"Darst","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2026.07.002_b0100","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-025-56944-1","article-title":"Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases","volume":"16","author":"Mitchell","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.euros.2026.07.002_b0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41585-019-0164-8","article-title":"The influence of BRCA2 mutation on localized prostate cancer","volume":"16","author":"Taylor","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2026.07.002_b0110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.002_b0115","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2026.07.002_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1234973","article-title":"PARP inhibitors combined with radiotherapy: are we ready?","volume":"14","author":"Sun","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.euros.2026.07.002_b0125","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.euros.2026.07.002_b0130","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/s41375-025-02635-1","article-title":"Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants","volume":"39","author":"Stubbins","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.euros.2026.07.002_b0135","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/jamaoncol.2018.6477","article-title":"Association of inherited pathogenic variants in checkpoint kinase 2 (CHEK2) with susceptibility to testicular germ cell tumors","volume":"5","author":"AlDubayan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euros.2026.07.002_b0140","first-page":"2720","article-title":"Increased prevalence of germline pathogenic CHEK2 variants in individuals with pituitary adenomas","volume":"109","author":"De Sousa","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.euros.2026.07.002_b0145","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djaa095","article-title":"Pathogenic ATM mutations in cancer and a genetic basis for radiotherapeutic efficacy","volume":"113","author":"Pitter","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euros.2026.07.002_b0150","doi-asserted-by":"crossref","first-page":"10312","DOI":"10.18632\/oncotarget.14400","article-title":"Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:43:07Z","timestamp":1788291787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326006531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S2666168326006531"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.07.002","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Impact of Germline Pathogenic Variants in High-risk Prostate Cancer Treated with Radiotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}